Alpha Tau Medical Ltd., (DRTS): Price and Financial Metrics

Alpha Tau Medical Ltd., (DRTS): $2.56

0.10 (-3.76%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add DRTS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#244 of 360

in industry

DRTS Price/Volume Stats

Current price $2.56 52-week high $4.80
Prev. close $2.66 52-week low $2.55
Day low $2.55 Volume 47,700
Day high $2.68 Avg. volume 32,026
50-day MA $2.95 Dividend yield N/A
200-day MA $3.28 Market Cap 178.36M

DRTS Stock Price Chart Interactive Chart >


Alpha Tau Medical Ltd., (DRTS) Company Bio


Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.


DRTS Latest News Stream


Event/Time News Detail
Loading, please wait...

DRTS Latest Social Stream


Loading social stream, please wait...

View Full DRTS Social Stream

Latest DRTS News From Around the Web

Below are the latest news stories about ALPHA TAU MEDICAL LTD that investors may wish to consider to help them evaluate DRTS as an investment opportunity.

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

- The overview presentation will review some of the Company’s recent achievements, including highly promising interim results from the Company’s pancreatic cancer safety and feasibility trial as well as robust long-term data analyzed across four clinical trials - - The Company will also be featured at the Biotech Showcase™ occurring in parallel, and will host institutional investor meetings at both conferences - JERUSALEM, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or

Yahoo | December 20, 2023

Sidoti Events, LLC's Virtual December Small-Cap Conference

NEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December ...

Yahoo | December 5, 2023

Alpha Tau to Participate in Sidoti Small-Cap Conference

JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will present at the Sidoti Small-Cap Virtual Conference on Thursday, December 7th, 2023. Format:Presentation and 1-on-1 meetingsDate:December 7th, 2023Time:9:15 AM ETLocation:VirtualRegistration:https://sidoti.zoom.us/webinar/register/WN_VNDWwCEtSeySoAVKVx38YQ About Al

Yahoo | November 29, 2023

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events - - First five patients received conservative partial tumor coverage, and in patients with higher radium-224 levels, increased tumor responses were observed, with the last three patients presenting two stable disease responses and one partial response at last measurement - JERUSALEM, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical

Yahoo | November 28, 2023

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“HekaBio”) a Japan-based healthcare investment, development and commercialization platform which is partnered with Alpha Tau, announced today that Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) has accepted Alpha Tau’s submission requesting shonin pre-market approval of Alpha DaRT in pat

Yahoo | November 20, 2023

Read More 'DRTS' Stories Here

DRTS Price Returns

1-mo -13.80%
3-mo -16.07%
6-mo -23.12%
1-year -10.18%
3-year N/A
5-year N/A
YTD -14.95%
2023 -5.35%
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!